NFKB1 and neoplasm: By using both the NF-kB pharmacological inhibitors, BMS-345541 and I-BET151, and siRNA for NF-kB subunits, they have proven that IFN-γ released by tumor-infiltrating lymphocytes up-regulates PD-L1 expression on melanoma cells (112).